close
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 14;21(46):12989-95.
doi: 10.3748/wjg.v21.i46.12989.

Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis

Yuki Haga  1 , Tatsuo Kanda  1 , Reina Sasaki  1 , Masato Nakamura  1 , Shingo Nakamoto  1 , Osamu Yokosuka  1
Affiliations
Review

Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis

Yuki Haga et al. World J Gastroenterol. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) is globally increasing and has become a world-wide health problem. Chronic infection with hepatitis B virus or hepatitis C virus (HCV) is associated with hepatic steatosis. Viral hepatitis-associated hepatic steatosis is often caused by metabolic syndrome including obesity, type 2 diabetes mellitus and/or dyslipidemia. It has been reported that HCV genotype 3 exerts direct metabolic effects that lead to hepatic steatosis. In this review, the differences between NAFLD/NASH and viral hepatitis-associated steatosis are discussed.

Keywords: Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of hepatic steatosis induced by viral and non-viral pathways. HBV: Hepatitis B virus; HBx: Hepatitis B X protein; HCV: Hepatitis C virus; SREBP1: Sterol regulatory element-binding protein-1; PPARγ: Peroxisome proliferator-activated receptor gamma.
See this image and copyright information in PMC

References

    1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–384. - PubMed
    1. Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism. 2014;63:161–167. - PubMed
    1. Yasui K, Harano Y, Mitsuyoshi H, Tsuji K, Endo M, Nakajima T, Minami M, Itoh Y, Zen Y, Nakanuma Y, et al. Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol. 2010;45:95–104. - PubMed
    1. Tsuzura H, Genda T, Sato S, Hirano K, Kanemitsu Y, Narita Y, Kikuchi T, Iijima K, Wada R, Ichida T. Association of visceral obesity with high viral load and histological findings in elderly patients with genotype 1 chronic hepatitis C. Intern Med. 2013;52:1665–1673. - PubMed
    1. Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, Chang FY, Lee SD. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol. 2001;16:190–195. - PubMed

MeSH terms